CNC — Centene Corp. stock price, charts and financials

NYSE·Healthcare·Medical - Healthcare Plans·USA

Latest market price

64.07

+0.31+0.49%

Overview Short InterestFilings

CNCQT89Centene Corp.·NYSE

Overview Short InterestFilings

64.07+0.49%

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

HUM-3.30%$362.16 CI-2.84%$274.05 ELV-1.25%$378.00 MOH-1.75%$191.36 OSCR-1.17%$30.38 CVS-0.90%$104.42 ALHC-7.14%$13.52 UNH-1.84%$407.71

Snapshot

Index	S&P 500	P/E	-	EPS (ttm)	-10.44	Insider Own	2.81%	Shs Outstand	494.00M	Perf Week	0.25%

Market Cap	31.65B	Forward P/E	12.52	EPS next Y	5.12	Insider Trans	-0.58%	Shs Float	483.27M	Perf Month	-3.00%

Enterprise Value	20.70B	PEG	-	EPS next Q	0.10	Inst Own	-	Short Float	2.78%	Perf Quarter	19.62%

Income	-5.10B	P/S	0.16	EPS this Y	143.92%	Inst Trans	-	Short Ratio	2.34	Perf Half Y	49.70%

Sales	193.73B	P/B	1.40	EPS next Y	11.56%	ROA	-6.14%	Short Interest	13.44M	Perf YTD	55.70%

Book/sh	45.72	P/C	1.17	EPS next 5Y	18.36%	ROE	-24.03%	52W High	69.36 -7.63%	Perf Year	147.28%

Cash/sh	54.77	P/FCF	3.43	EPS past 3/5Y	-	ROIC	-12.90%	52W Low	25.08 155.46%	Perf 3Y	-3.19%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	10.45% 11.88%	Gross Margin	16.13%	Volatility	3.72% 3.92%	Perf 5Y	-9.08%

Dividend TTM	-	EV/Sales	0.11	EPS Y/Y TTM	-265.45%	Oper. Margin	-2.82%	ATR (14)	2.64	Perf 10Y	70.26%

Dividend Ex-Date	-	Quick Ratio	1.15	Sales Y/Y TTM	18.80%	Profit Margin	-2.63%	RSI (14)	49.97	Recom	2.41

Dividend Gr. 3/5Y	-	Current Ratio	1.15	EPS Q/Q	1668.75%	SMA20	-1.67%	Beta	1.08	Target Price	66.44

Payout	0.00%	Debt/Eq	0.94	Sales Q/Q	-8.96%	SMA50	0.34%	Rel Volume	1.13	Prev Close	63.76

Employees	61,100	LT Debt/Eq	0.93	Earnings	Oct 27	SMA200	36.68%	Avg Volume	5.35M	Price	64.07

IPO Date	Dec 13, 2001	Option/Short	Yes / Yes	EPS/Sales Surpr.	131.30% 12.47%	Net Debt/EBITDA	2.78	Volume	6,023,787	Change	0.49%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-03-26	Reiterated	Stifel Nicolaus	Buy	$79
Aug-03-26	Reiterated	Bernstein	Outperform	$59 → $79
Jul-29-26	Reiterated	Morgan Stanley	Equal Weight	$57 → $66
Jul-29-26	Reiterated	Robert W. Baird		$46 → $66
Jul-29-26	Reiterated	Barclays	Overweight	$75 → $80
Jul-14-26	Reiterated	Truist Securities	Buy	$71 → $78
Jul-13-26	Reiterated	Wells Fargo	Equal Weight	$44 → $69
Jul-07-26	Reiterated	Raymond James	Market Perform	$60 → $75
Jun-23-26	Initiated	RBC Capital	Sector Perform	$70
Jun-08-26	Reiterated	Mizuho	Neutral	$58 → $63

Latest News

Aug-03-26

Aug-03-2604:01PM

4 GARP Stocks With Discounted PEG Ratios and Strong Growth to Buy Nowzacks.com

10:41AM

Here's Why Centene (CNC) is a Strong Value Stockzacks.com

Jul-31-26

Jul-31-2604:04PM

UnitedHealth vs. Centene: Which Managed Care Stock Is the Better Buy?Yahoo

Jul-30-26

Jul-30-2611:03AM

Best Momentum Stock to Buy for July 30thzacks.com

10:41AM

Should Value Investors Buy Centene (CNC) Stock?zacks.com

Jul-29-26

Jul-29-2611:02AM

Centene Stock Q2 Earnings Call Highlights Margin Recoveryzacks.com

Jul-28-26

Jul-28-2605:23PM

Centene Corporation (CNC) Q2 2026 Earnings Call Transcriptseekingalpha.com

02:18PM

Centene Finds Profit Growth Even as Medicaid Membership Softensbenzinga.com

01:05PM

Centene Q2 Earnings Beat Estimates on Increasing Premiumszacks.com

10:31AM

Centene (CNC) Reports Q2 Earnings: What Key Metrics Have to Sayzacks.com

08:11AM

Centene (CNC) Q2 Earnings and Revenues Surpass Estimateszacks.com

07:07AM

Centene Reports $1 Billion Profit As Health Insurer's Costs Easeforbes.com

06:48AM

Centene Raises 2026 Outlook on Profit, Revenue Growthwsj.com

06:07AM

Centene raises annual profit forecast on better cost controlreuters.com

06:00AM

CENTENE CORPORATION REPORTS SECOND QUARTER 2026 RESULTSprnewswire.com

Company

Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	193,734	194,777	163,071	153,999	144,547	125,982	111,115	74,639	60,116
Cost of Goods Sold Incl. D&A	162,494	170,944	146,242	136,684	127,891	111,783	95,899	65,796	51,695
Gross Profit	31,240	23,833	16,829	17,315	16,656	14,199	15,216	8,843	8,421
Selling, General and Administrative Excl. Other	13,374	13,263	12,400	12,563	11,589	9,601	11,343	6,533	6,752
Research and Development	0	0	0	0	0	0	0	0	0
Other Operating Expense	23,325	18,189	1,254	1,822	3,749	2,814	791	529	211
Operating Income	-5,458	-7,618	3,175	2,930	1,318	1,784	3,082	1,781	1,458
Interest Expense	655	678	702	725	665	665	728	412	343
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	1,481	1,568	1,784	1,393	1,309	694	419	413	253
Net Income Before Taxes	-4,632	-6,728	4,257	3,598	1,962	1,813	2,773	1,782	1,368
Income Taxes	474	-51	963	899	760	477	979	473	474
Consolidated Net Income	-5,099	-6,673	3,305	2,702	1,202	1,347	1,808	1,321	900
Net Income From Continuing Operations	-5,104	-6,677	3,294	2,699	1,202	1,336	1,794	1,309	894
Net Income	-5,099	-6,673	3,305	2,702	1,202	1,347	1,808	1,321	900
EPS (Recurring)	-10.40	-13.61	6.33	4.97	2.09	2.31	3.17	3.19	2.31
EPS (Basic, Before Extraordinaries)	-10.40	-13.61	6.33	4.97	2.09	2.31	3.17	3.19	2.31
EPS (Diluted)	-10.44	-13.62	6.31	4.95	2.07	2.28	3.12	3.14	2.26
EBITDA	-2,893	-5,140	6,200	5,616	4,058	3,813	4,760	2,837	2,206
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	9.60	14.99	39.62	36.14	19.24	20.02	25.51
Price To Sales Ratio	0.16	0.10	0.19	0.26	0.33	0.38	0.31	0.35	0.37
Gross Margin	16.13	12.24	10.32	11.24	11.52	11.27	13.69	11.85	14.01
Operating Margin	-2.82	-3.91	1.95	1.90	0.91	1.42	2.77	2.39	2.43
Net Margin	-2.63	-3.43	2.03	1.75	0.83	1.07	1.63	1.77	1.50
Shares Outstanding	494	491	522	543	575	583	571	413	390
Market Capitalization	31,651	20,205	31,623	40,296	47,156	48,039	34,277	25,965	22,484
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burdick Kenneth A	Director	Jun 10 '26	Sale	64.55	80,000	5,164,000	197,086	Jun 11
Burdick Kenneth A	Director	Dec 04 '25	Sale	39.00	32,796	1,279,044	272,365	Dec 05
Burdick Kenneth A	Director	Dec 03 '25	Sale	39.04	33,211	1,296,557	305,161	Dec 05
LONDON SARAH	Chief Executive Officer	Aug 08 '25	Buy	25.50	19,230	490,365	845,275	Aug 11
Samuels Theodore R. II	Director	Jul 28 '25	Buy	27.62	9,000	248,580	32,000	Jul 29
Greco Thomas	Director	Dec 18 '24	Buy	59.75	17,000	1,015,750	19,309	Dec 19
Dallas H James	Director	Dec 16 '24	Buy	59.01	1,693	99,904	1,693	Dec 17
BLUME JESSICA L.	Director	Dec 16 '24	Buy	59.48	250	14,870	250	Dec 17
COUGHLIN CHRISTOPHER J	Director	Dec 16 '24	Buy	59.44	10,000	594,400	36,358	Dec 17
Samuels Theodore R. II	Director	Dec 13 '24	Buy	58.86	5,000	294,300	23,000	Dec 17
Asher Andrew Lynn	Chief Financial Officer	Nov 13 '24	Buy	58.14	17,200	1,000,008	486,847	Nov 13
LONDON SARAH	Chief Executive Officer	Nov 08 '24	Buy	60.80	4,117	250,314	667,229	Nov 08
COUGHLIN CHRISTOPHER J	Director	May 14 '24	Sale	76.75	878	67,382	0	May 24
FASOLA KENNETH J	President	May 13 '24	Sale	77.62	8,000	620,960	300,357	May 15
Robinson Lori Jean	Director	Feb 13 '24	Option Exercise	54.65	10,000	546,500	21,455	Feb 15

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.